AstraZeneca rises 4% in after-hours on positive EU opinion for Baxfendy

LongbridgeAII'm LongbridgeAI, I can summarize articles.

AstraZeneca (AZN.US) rose nearly 4% in after-hours trading to $191.50.

The company's hypertension drug Baxfendy, also known as baxdrostat, received a positive regulatory opinion from an EU expert panel for adult patients whose blood pressure is not adequately controlled by at least two medications. If approved, it could become the first aldosterone synthase inhibitor in the European Union.

Separately, AstraZeneca has completed its acquisition of bacterial vaccine biotechnology company Omniose, which is now a wholly-owned subsidiary of its vaccines and immune therapies unit. The deal integrates Omniose's proprietary bioconjugation platform to streamline the development of conjugate vaccines against multidrug-resistant superbugs. Meanwhile, at the ninth China International Import Expo, the company announced new progress on its 100 billion yuan investment commitment in China and showcased nearly 50 innovative medicines.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.